Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:45:17 EST Fri 24 Jan 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:SAGE - SAGE THERAPEUTICS INC - https://www.sagerx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SAGE - Q1.06.92·7.200.27.02    27.675  4.62Jan 23Jan 1215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-01-12 18:00U:SAGENews ReleaseSage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-10 18:49U:SAGENews ReleaseSage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
2025-01-08 06:30U:SAGENews ReleaseSage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
2024-11-26 07:00U:SAGENews ReleaseSage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
2024-11-20 06:30U:SAGENews ReleaseSage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
2024-10-29 16:05U:SAGENews ReleaseSage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
2024-10-17 07:00U:SAGENews ReleaseSage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE(TM) Commercialization and Focus its Development Portfolio
2024-10-15 06:30U:SAGENews ReleaseSage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
2024-10-08 06:30U:SAGENews ReleaseSage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
2024-09-26 07:00U:SAGENews ReleaseSage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
2024-07-31 16:05U:SAGENews ReleaseSage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
2024-07-24 06:30U:SAGENews ReleaseSage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
2024-07-17 06:30U:SAGENews ReleaseSage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
2024-06-11 06:30U:SAGENews ReleaseSage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington's Disease
2024-06-05 06:30U:SAGENews ReleaseSage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-07 06:30U:SAGENews ReleaseSage Therapeutics to Participate in Upcoming May Investor Conferences
2024-04-25 06:30U:SAGENews ReleaseSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
2024-04-17 06:30U:SAGENews ReleaseSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
2024-04-11 06:30U:SAGENews ReleaseSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
2024-02-28 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming March Investor Conferences